---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-060481"
form_type: "8-K"
ticker: "CGEM"
cik: "0001789972"
company_name: "Cullinan Therapeutics, Inc."
filed_at: "2024-05-15T23:59:59+00:00"
generated_at: "2026-06-01T23:25:12.968251+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cullinan Q1 net loss $37.3M; cash $434.8M; plans CLN-978 autoimmune IND Q3 2024; Meek appointed director

## Summary
- Cash, cash equivalents, investments $434.8M as of March 31, 2024; plus $280M April private placement extends cash runway into 2028.
- Q1 net loss $37.3M vs $58.1M Q1 2023; R&D expenses $30.6M, G&A $12.3M.
- CLN-978 development pivoted to autoimmune diseases; IND for SLE expected Q3 2024; B-NHL study discontinued.
- David Meek appointed to board effective May 15; Thomas Ebeling to resign June 26.
- Initial CLN-619 combination & monotherapy data to be presented at ASCO June 1, 2024.

## SEC filing metadata
- accession: 0000950170-24-060481
- form_type: 8-K
- ticker: CGEM
- cik: 0001789972
- company_name: Cullinan Therapeutics, Inc.
- filed_at: 2024-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/cgem-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-060481
- JSON: https://secwatch.observer/filing/0000950170-24-060481.json
- Plain text: https://secwatch.observer/filing/0000950170-24-060481.txt

## Key facts
- Earnings Releases
  Cullinan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss (before items attributable to noncontrolling interest) for the first quarter of 2024 was $37.3 million.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss (before items attributable to noncontrolling interest) for the first quarter of 2024 was $37.3 million
  - Result: reported results
  source text: Cullinan Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm
- Executive change
  David Meek was appointed as Class I Director at Cullinan Therapeutics, Inc..
  - Action: appointed
  - Role: Class I Director
  source text: the Board of Directors (the “Board”) of the Company appointed David Meek as a Class I director, effective May 15, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm
- Executive change
  Thomas Ebeling resigned as Director at Cullinan Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Thomas Ebeling notified the Board of his intention to serve out his current term and resign as a director effective as of June 26, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789972/000095017024060481/0000950170-24-060481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.